Brazil Pharmaceutical Excipients Market Set to Reach USD 418.1 Million by 2030: Increasing Pharma Manufacturing and Growing Demand for Generic Drugs Drive Growth

Infinium Global Research has added a new report on Brazil Pharmaceutical Excipients Market. The report covers the analysis of regional markets of Brazil. Moreover, the report gives insights into the factors that affect the regional performance of the market in the short run and in the long run. The Brazil pharmaceutical excipients market is a customer intelligence and competitive study of the demand, forecasts, trends, and macro indicators in Brazil market. The dynamics including drivers, restraints, opportunities, political, socioeconomic factors, technological factors, key trends, and future prospects. The Brazil pharmaceutical excipients market, which was valued at USD 225.1 million in 2022, is poised for remarkable expansion and is projected to reach USD 418.1 million by 2030, exhibiting a robust Compound Annual Growth Rate (CAGR) of 9.25% during the forecast period.

To Know More Request a Sample of this Report: https://www.infiniumglobalresearch.com/brazil/sample-request/2337

Thriving Pharma Manufacturing Landscape

Brazil's pharmaceutical manufacturing landscape has undergone significant growth, positioning itself to serve other emerging South American markets. With its status as the world's fifth-largest country and the largest in South America, Brazil boasts the sixth-largest global population. Notably, approximately 66% of companies with manufacturing sites in Brazil are domestically owned, and the country also hosts three US-based pharmaceutical manufacturers. International companies investing in Brazil's pharmaceutical manufacturing sector are expected to realize higher returns on investment compared to developed market equivalents. Additionally, Brazil's aging population is set to increase the demand for age-related disease treatments, such as those related to oncology and hypertension, further driving domestic pharma production.

Rising Demand for Generic Drugs

The global trend of increased use of generic drugs has found a significant foothold in Brazil's pharmaceutical market. With its vast population of nearly 210 million, Brazil represents a substantial market for pharmaceuticals. In fact, Brazil's pharmaceutical industry is the third-largest in the Americas region, following the USA and Canada. Since the introduction of generic drugs in 2001, Brazil's pharmaceutical landscape has transformed significantly. Generic drugs have gained substantial market share and currently constitute a significant portion of the total pharmaceutical market. In 2018, the Brazilian Ministry of Economy registered 418 pharmaceutical manufacturing plants in the country. Excipients, which are inactive ingredients in pharmaceutical formulations, play a vital role in drug development, and the production of generic drugs is anticipated to drive demand for pharmaceutical excipients in Brazil.

Evolving Regulatory Landscape

The Health Regulatory Agency of Brazil, ANVISA, has introduced landmark regulations pertaining to pharmaceutical excipients and active pharmaceutical ingredients (APIs). These regulations aim to establish a clear and distinct regulatory process in Brazil while aligning with international practices. Pharmaceutical manufacturers faced challenges in implementing these guidelines, including performing risk assessments of their excipient suppliers to determine Good Manufacturing Practices (GMP) expectations. Meeting the GMP requirements came with significant initial expenses, impacting the profitability of excipient manufacturers and potentially impeding market growth. However, the overall impact of this factor is expected to be limited, as it will create opportunities for the development of novel excipients in the market.

Focus on Novel Excipients and Drug Delivery Systems

To enable the development of novel drug delivery systems and biotechnology-derived drugs, the demand for new excipients continues to rise. The pharmaceutical industry is actively developing multifunctional excipients capable of improving solubility, absorption, disintegration, and stability, particularly for parenteral formulations. These excipients are designed to be biologically inactive, potentially addressing the current shortage of new drug formulations. Furthermore, nanotechnology-enabled and liposomal delivery systems are gaining traction in the market. Co-processed excipients are also expected to gain market approval more rapidly than entirely new chemical entities. As such, the increasing focus on the development of novel pharmaceutical excipients presents promising opportunities within the market.

Enquire Here Get Customization & Check the Discount for the Report @ https://www.infiniumglobalresearch.com/brazil/customization/2337

Table of Content

Chapter 1. Report Overview

1.1. Report Description

1.2. Research Methods

1.3. Research Approaches

Chapter 2. Executive Summary

Chapter 3. Market Overview

3.1. Introduction

3.2. Market Dynamics

3.2.1. Drivers

3.2.2. Restraints

3.2.3. Opportunities

3.2.4. Challenges

3.3. PEST-Analysis

3.4. Porter's Diamond Model for Brazil Pharmaceutical Excipients Market

3.5. IGR-Growth Matrix Analysis

3.6. Competitive Landscape in Brazil Pharmaceutical Excipients Market

Chapter 4. Brazil Pharmaceutical Excipients Market by Type

4.1. Organic

4.2. Inorganic

Chapter 5. Brazil Pharmaceutical Excipients Market by Functionality

5.1. Binders & Fillers

5.2. Coating Agents

5.3. Disintegrants

5.4. Flavoring Agents and Colorants

5.5. Lubricants and Glidants

5.6. Sweeteners

5.7. Preservatives & Antioxidants

5.8. Others

Chapter 6. Company Profiles

6.2.1 Croda International Plc

6.2.1.1 Overview

6.2.1.2 Company Overview

6.2.1.3 Financial Snapshot

6.2.1.4 Product Portfolio

6.2.2 MEGGLE Group GmbH

6.2.2.1 Overview

6.2.2.2 Company Overview

6.2.2.3 Product Portfolio

6.2.3 Cargill, Incorporated

6.2.3.1 Overview

6.2.3.2 Company Overview

6.2.3.3 Product Portfolio

6.2.4 DOW

6.2.4.1 Overview

6.2.4.2 Company Overview

6.2.4.3 Product Portfolio

6.2.5 Roquette Freres

6.2.5.1 Overview

6.2.5.2 Company Overview

6.2.5.3 Product Portfolio

More Insights on this report, Speak to Our Analyst: https://www.infiniumglobalresearch.com/brazil/enquiry/2337

Reasons to Buy this Report:

=> Comprehensive analysis of regional markets of Brazil pharmaceutical excipients.

=> Complete coverage of all the product types and application segments to analyze the trends, developments, and forecast of market size up to 2030.

=> Comprehensive analysis of the companies operating in this market. The company profile includes an analysis of the product portfolio, revenue, SWOT analysis, and the latest developments of the company.

=> Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus on to invest, consolidate, expand, and/or diversify.

2nd Floor, Ganadish Empire, Rahatani Chowk, Pimple Saudagar, Pimpri-Chinchwad, Maharashtra 411027

About Infinium Global Research:

Infinium Global Research is a business consulting and market research firm; a group of experts that caters to fulfilling business and market research needs of leading companies in various industry verticals and business segments. The company also serves government bodies, institutes, and non-profit/non-government organizations to meet their knowledge and information needs.
Through our information services and solutions, we assist our clients to improve their performance and assess the market conditions to achieve their organizational goals. Our team of experts and analysts are engaged in continuously monitoring and assessing the market conditions to provide knowledge support to our clients. To help our clients and to stay updated with the advances and inventions in technology, business processes, regulations, and the environment, Infinium often conducts regular meets with industry experts and opinion leaders. Our key opinion leaders are involved in monitoring and assessing the progress in the business environment, so as to offer the best opinion to our clients.

This release was published on openPR.